Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer

被引：0
|
作者：
de la Calle, Claire Marie
Chang, Albert
Rashid, Ghezal
Wong, Anthony C.
Choi, Alice
Feng, Felix Y.
Gottschalk, Alexander R.
Menzel, Paul Lawrence
Carroll, Peter
Hao Gia Nguyen
机构：
[1] UCSF, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[4] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] CPMC, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
323
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Improving outcomes in high-risk prostate cancer with radiotherapy
    Polkinghorn, William R.
    Zelefsky, Michael J.
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2013, 18 (06) : 333 - 337
  • [32] Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
    Freedland, S. J.
    Gleave, M. E.
    De Giorgi, U. F. F.
    Rannikko, A.
    Pieczonka, C.
    Sridharan, S.
    Brasso, K.
    Woo, H.
    Caamano, A. Gomez
    Saranchuk, J.
    Nordquist, L. T.
    Ferreira, U.
    Tang, Y.
    Rosbrook, B.
    Haas, G. P.
    Rosales, M.
    Zohren, F.
    Shore, N. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S961 - S961
  • [33] Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
    Dawson, NA
    Figg, WD
    Cooper, MR
    Sartor, O
    Bergan, RC
    Senderowicz, AM
    Steinberg, SM
    Tompkins, A
    Weinberger, B
    Sausville, EA
    Reed, E
    Myers, CE
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1470 - 1477
  • [34] TREATMENT WITH ENZALUTAMIDE IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER FROM THE EMBARK TRIAL: NURSING IMPLICATIONS
    Williams, Monique
    Freedland, Stephen J.
    Huebner, Tamara
    De Giorgi, Ugo
    Shore, Neal D.
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [35] Comparison of the Efficacy of Definitive Radiotherapy and Radical Prostatectomy in High-Risk Prostate Cancer: A Single-Center Experience
    Inanc, Berrin
    Mermut, Ozlem
    Yucetas, Ugur
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2021, 20 (04): : 225 - 230
  • [36] Phase II study of neoadjuvant 'supercastration' in men with high-risk prostate cancer
    Corcoran, N.
    Howard, N.
    Bugeja, P.
    Kerger, M.
    Moon, D.
    Clarke, D.
    Grummet, J.
    Hovens, C.
    Costello, T.
    Pedersen, J.
    Ryan, A.
    Ruljancich, P.
    Parente, P.
    BJU INTERNATIONAL, 2014, 113 : 18 - 18
  • [37] The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
    Layton, Jodi Lyn
    Plette, Angela Marie
    Renzulli, Joseph F.
    Miller, E. Bradley
    Safran, Howard
    Mega, Anthony E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [38] FEASIBILITY OF RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT IXABEPILONE FOR HIGH-RISK PROSTATE CANCER: A PHASE II CLINICAL TRIAL
    Maddox, Michael
    Layton, Jodi
    Taber, Angela
    Mega, Anthony
    Renzulli, Joseph, II
    JOURNAL OF UROLOGY, 2013, 189 (04): : E314 - E315
  • [39] Phase II trial of pelvic nodal irradiation with hypofractionated IMRT-SIB for high-risk prostate cancer
    Magli, A.
    Ceschia, T.
    Moretti, E.
    Signor, M.
    Polsinelli, M.
    Prisco, A.
    Crespi, M.
    Foti, C.
    Malisan, M. R.
    Fongione, S.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S91 - S91
  • [40] Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
    Nikitas, John
    Lam, Ethan
    Booker, Kiara Adame
    Fendler, Wolfgang P.
    Eiber, Matthias
    Hadaschik, Boris
    Herrmann, Ken
    Hirmas, Nader
    Lanzafame, Helena
    Stuschke, Martin
    Czernin, Johannes
    Steinberg, Michael L.
    Nickols, Nicholas G.
    Kishan, Amar U.
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (07) : 1076 - 1079
12345